These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 2194510)

  • 1. Time-related changes in plasma adrenal steroids during treatment with spironolactone in primary aldosteronism.
    Sakamoto H; Ichikawa S; Sakamaki T; Nakamura T; Ono Z; Takayama Y; Murata K
    Am J Hypertens; 1990 Jul; 3(7):533-7. PubMed ID: 2194510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of atrial natriuretic peptide in mineralocorticoid escape phenomenon in patients with primary aldosteronism.
    Nakamura T; Ichikawa S; Sakamaki T; Sato K; Kogure M; Tajima Y; Kato T; Murata K
    Proc Soc Exp Biol Med; 1987 Sep; 185(4):448-54. PubMed ID: 2956609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary aldosteronism: effects of inhibition of ACTH and potassium administration on plasma aldosterone concentration.
    Ganguly A; Luetscher JA; Weinberger MH
    Clin Exp Hypertens A; 1982; 4(9-10):1695-714. PubMed ID: 6291813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism.
    Biglieri EG; Schambelan M
    J Clin Endocrinol Metab; 1979 Jul; 49(1):87-91. PubMed ID: 447820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentration of aldosterone, 18-hydroxy-deoxycorticosterone and cortisol in adrenal veins of patients with low-renin hypertension.
    Horký K; Gregorová I; Tomsová Z; Vancura J; Silinková-Málková E
    Horm Metab Res; 1977 Sep; 9(5):403-9. PubMed ID: 200537
    [No Abstract]   [Full Text] [Related]  

  • 6. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mineralocorticoid hormone pathways in hypertension with hyperaldosteronism.
    Biglieri EG; Kater CE; Brust N; Chang B; Hirai J
    Clin Exp Hypertens A; 1982; 4(9-10):1677-83. PubMed ID: 7139973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism.
    Ichikawa S; Tajima Y; Sakamaki T; Matsuo H; Kogure M; Hirano Y; Yagi S; Murata K
    Jpn Circ J; 1984 Nov; 48(11):1184-96. PubMed ID: 6502914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-four year spironolactone therapy in an aged patient with aldosterone-producing adenoma.
    Takeda R; Yamazaki T; Ito Y; Koshida H; Morise T; Miyamori I; Hashimoto T; Morimoto S
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):186-90. PubMed ID: 1311894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of impaired aldosterone response to spironolactone-induced renin and potassium elevations in adenomatous but not hyperplastic primary aldosteronism.
    Kater CE; Biglieri EG; Schambelan M; Arteaga E
    Hypertension; 1983; 5(6 Pt 3):V115-21. PubMed ID: 6360878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic value of calcium antagonists in autonomous hyperaldosteronism.
    Stimpel M; Ivens K; Volkmann HP; Wambach G; Kaufmann W
    Klin Wochenschr; 1989 Feb; 67(4):248-52. PubMed ID: 2648061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced aldosterone secretion during spironolactone treatment in primary aldosteronism: report of a case.
    Sundsfjord JA; Marton P; Jorgensen H; Aakvaag A
    J Clin Endocrinol Metab; 1974 Oct; 39(4):734-9. PubMed ID: 4370321
    [No Abstract]   [Full Text] [Related]  

  • 13. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism.
    Tanabe A; Naruse M; Takagi S; Tsuchiya K; Imaki T; Takano K
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2489-94. PubMed ID: 12788844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone and other mineralocorticoids in Bartter's syndrome.
    Saruta T; Fujimaki M; Senba S; Saito I; Konishi K
    J Lab Clin Med; 1984 Jun; 103(6):848-53. PubMed ID: 6373989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage.
    Oelkers W; Diederich S; Bähr V
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3266-70. PubMed ID: 10999820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.
    Brown JJ; Davies DL; Ferriss JB; Fraser R; Haywood E; Lever AF; Robertson JI
    Br Med J; 1972 Jun; 2(5816):729-34. PubMed ID: 4338668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective hypoaldosteronism with hyperreninemia in a diabetic patient.
    Morimoto S; Kim KS; Yamamoto I; Uchida K; Takeda R; Kornel L
    J Clin Endocrinol Metab; 1979 Nov; 49(5):742-7. PubMed ID: 489714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and treatment of primary aldosteronism].
    Wang GY
    Zhonghua Wai Ke Za Zhi; 1992 Nov; 30(11):677-9, 700. PubMed ID: 1307299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma.
    Irony I; Kater CE; Biglieri EG; Shackleton CH
    Am J Hypertens; 1990 Jul; 3(7):576-82. PubMed ID: 2194512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing.
    Hood S; Cannon J; Foo R; Brown M
    Clin Med (Lond); 2005; 5(1):55-60. PubMed ID: 15745200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.